Menu

Polydextrose

Also known as: E1200, PDX fiber

A manufactured soluble glucose polymer with food-texture uses and inconsistent constipation findings; fiber grams do not guarantee a specific bowel effect.

Fine off-white powder in a stoneware dish on folded parchment
Editorial illustration

Polydextrose is a manufactured, water-soluble glucose polymer used for food bulk and texture and studied as a fiber ingredient. Adult constipation trials have mixed results, including a negative transit-time endpoint. Its food-additive safety assessment does not establish a constipation treatment or universal digestive tolerance.1, 2, 3, 4

  • The 2018 trial randomized 128 adults to 8 or 12 g/day or placebo; the primary transit endpoint was assessed after two weeks.3
  • The 2019 trial used 4, 8 or 12 g/day for two weeks, but its recruited population was not sufficiently constipated at baseline.4
  • The U.S. rule requires a laxative-effect warning when a single serving would be expected to exceed 15 g.1

What is Polydextrose?

The U.S. rule describes a polymer made from glucose, sorbitol and an acid catalyst. It is not dextrose sugar or a live probiotic. EFSA describes limited absorption and partial fermentation in the large intestine; that process alone does not prove a particular clinical outcome.1, 2

Where it comes from

Natural sources

  • Glucose-based raw materials, rather than an intact botanical fiber

How it's made

A manufactured condensation polymer; its specifications and processed forms are defined in the food-additive rule.

What it does in products

  • Food bulking and texture
  • Humectant or formulation aid
  • Fiber ingredient in studied oral preparations

Benefits

Some bowel findings, without a consistent transit benefit

limited evidence

One trial reported more bowel movements at its highest exposure, while another did not confirm faster transit or consistent stool changes.3, 4

The 2018 study's primary transit endpoint was negative, with limited symptom-subscale changes. The 2019 abstract reports increased bowel movements at 12 g/day but acknowledges a weakly constipated baseline population. Different endpoints and enrollment problems prevent a dependable individual treatment estimate.

Evidence scope and limitations

Specified food-additive uses and two adult constipation studies; not every fiber claim, mixture, microbiome outcome or gastrointestinal diagnosis.

  • Two- to four-week studies cannot establish lifelong benefit or safety in excluded populations.
  • Primary transit results and secondary symptom scores must not be conflated.
  • The 2019 primary abstract was checked; additional unseen results or formulations are not inferred.
  • The final EFSA assessment was checked through indexed original text after live retrieval failed; a safety conclusion is not an efficacy ruling.

Evidence last checked: 2026-10-15

Side effects & safety

Laxative effects or digestive discomfort at poorly tolerated exposure (varies)The food rule's warning and EFSA's discussion of laxation make tolerance relevant. No numerical ADI needed for assessed uses does not mean unlimited intake is comfortable.

Safety considerations

  • The 2018 trial excluded pregnancy and breastfeeding; its results do not establish a supplement regimen in either setting.
  • That trial also excluded medicines likely to alter gastrointestinal motility. Its results are not a comprehensive interaction assessment.
  • Not for: The assessed food uses and selected adult trials do not clear every gastrointestinal disorder or pediatric application.
  • Not for: Do not treat a tolerability-related loose stool as proof that an underlying constipation disorder has been corrected.
1, 2, 3

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

The trials studied 4–12 g/day for two to four weeks, with different measurement schedules and preparations; these are research exposures, not personal instructions. The 15 g single-serving labeling trigger is a regulatory condition, not a safe ceiling or recommended intake.

3, 4, 1

Regulatory status

  • 21 CFR 172.841 permits specified food-grade polydextrose under good manufacturing practice for defined technical functions, with exclusions including baby food and infant formula. EFSA's 2021 assessment found no safety concern for reported uses and no need for a numerical ADI; neither conclusion approves constipation-treatment claims.
1, 2

A negative primary endpoint should not disappear behind a fiber label

In the 2018 four-week intervention, the primary transit measurement was at two weeks, not the end of the full treatment period. Some patient-reported subscales changed, but that does not turn the transit result positive. In the 2019 experiment, baseline bowel frequency made the intended constipation population questionable.

A useful label question is therefore which outcome the exact preparation improved, compared with what, and in whom. Counting a polymer as a fiber ingredient or observing fermentation is not a substitute for that comparison.

3, 4, 2

Frequently asked questions

Does the word fiber guarantee that polydextrose works like psyllium?

No. The cited polydextrose trials have their own endpoints and limitations. A general category label cannot transfer another fiber's results to this polymer.3, 4

Is the 15 g label-warning trigger a recommended amount?

No. It specifies when the U.S. warning is required for a serving; it is not a recommended dose or a guarantee of tolerance below that amount.1, 2

The bottom line

Separate food formulation, digestive tolerance and the specific bowel endpoint; a fiber claim cannot answer all three.

References

  1. 21 CFR 172.841: Polydextrose. Electronic Code of Federal Regulations · government guidance · Identity, food uses and single-serving laxative-warning condition checked October 15, 2026; continuously maintained rule
  2. EFSA Panel on Food Additives and Flavourings. Re-evaluation of polydextrose (E 1200) as a food additive. EFSA Journal (2021) · safety assessment · DOI 10.2903/j.efsa.2021.6363; indexed final assessment checked; live Wiley retrieval failed
  3. Duncan PI, Enters-Weijnen CF, Emami N, et al.. Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial. Nutrients (2018) · randomized trial · PMID 30029461; DOI 10.3390/nu10070920; NCT02234518; indexed primary abstract and original methods/results checked
  4. Ibarra A, Pelipyagina T, Rueffer M, Evans M, Ouwehand AC. Efficacy of Polydextrose Supplementation on Colonic Transit Time, Bowel Movements, and Gastrointestinal Symptoms in Adults: A Double-Blind, Randomized, Placebo-Controlled Trial. Nutrients (2019) · randomized trial · PMID 30791557; DOI 10.3390/nu11020439; indexed primary abstract checked; full-text details not inferred

Revision history

  1. Initial AI-assisted source checks and claim-level citation mapping under the site-authorized publishing workflow. No separate human or independent medical review is claimed.